Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

1612 - Tumor infiltrating lymphocytes (TILs) and PDL1 expression as prescreening enrichment biomarkers of clinical benefit to immune checkpoint inhibitors (CI) in early clinical trials (ECT)

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Presenters

Juan Martin-Liberal

Citation

Annals of Oncology (2018) 29 (suppl_8): viii14-viii57. 10.1093/annonc/mdy269

Authors

J. Martin-Liberal1, F. Pagliuca2, C. Hierro1, C. Viaplana3, E. Muñoz Couselo4, J. Capdevila Castillon5, I. Matos4, L. Fariñas Madrid4, E. Zamora4, I. Braña Garcia4, E. Elez Fernandez4, M. Ochoa De Olza Amat4, A. Azaro4, M. Alsina4, M. Vieito Villar1, R. Fasani1, J. Tabernero4, E. Garralda6, R. Dienstmann3, P.G. Nuciforo7

Author affiliations

  • 1 Oncology, Vall d`Hebron Institute of Oncology (VHIO)-Cellex Center, 08035 - Barcelona/ES
  • 2 Department Of Advanced Biomedical Sciences, Pathology Section, University of Naples Federico II, 80138 - Naples/IT
  • 3 Oncology Data Science (odyssey) Group, Vall d'Hebron University Hospital, 08035 - Barcelona/ES
  • 4 Medical Oncology, Vall d'Hebron University Hospital, 08035 - Barcelona/ES
  • 5 Gastrointestinal And Endocrine Tumor Unit, Vall d'Hebron University Hospital, 08035 - Barcelona/ES
  • 6 Early Drug Development Unit, Vall d`Hebron Institute of Oncology (VHIO)-Cellex Center, 08035 - Barcelona/ES
  • 7 Molecular Oncology, Vall d'Hebron University Hospital, 08035 - Barcelona/ES
More

Resources

Abstract 1612

Background

Patients (pts) enrolled in ECT with CI are mainly selected based on tumor type. Genomic markers are informative in few cases. We assessed microenvironment markers as prescreening tool to identify pts with higher chances of clinical benefit from CI.

Methods

Pts treated with anti PD1/PDL1 drugs in monotherapy or in combination with other CI in ECT at our centre were evaluated for TILs on hematoxylin-eosin stained sections and PDL1 expression in tumor (tumcells) and immune cells (immcells) by immunohistochemistry (SP263 antibody). Results were correlated with clinical outcomes.

Results

From June 16 to June 17, 64 pts were recruited. TILs and PDL1 expression were available for all and 39 pts, respectively. Tumor types were melanoma (16 pts), neuroendocrine (9), gyne (8), breast (5), H&N (4), others (22). In total, 38 pts received anti PD1/PDL1 in monotherapy, the rest received anti PD1/PDL1 based combinations (12 pts had prior CI treatment). Response rate (RR) was 22%; median PFS was 4 months (m) (CI95% 3.30-5.57). We found no differences in PDL1 expression in tumcells according to tumor type (Kruskal test p = 0.33) and a weak correlation between TILs and PDL1 in tumcells (Pearson 0.44; p = 0.004) or immcells (Pearson 0.57; p = 0.0001). Median TILs was 7% (range 1-90), with no difference according to tumor type (Kruskal test p = 0.45). Median TILs was higher in pts with response to CI (17.5% v 5%, Kruskal test p = 0.06). RR in pts with TILs ≥7% was 32% v 9% if TILs <7% (Fisher test p = 0.06). In a multivariable logistic model adjusting for tumor type and CI regimen, RR was significantly higher in pts with TILs ≥7% (odds ratio 8.2; p = 0.05). Median PFS in pts with TILs ≥7% was 5 m v 3.7 m if TILs <7% (HR = 0.57 in a multivariable Cox model, p = 0.06). In univariate models, there was a trend for higher RR if PDL1 ≥1% in tumcells (35% v 12%, fisher test p = 0.28) or if PDL1 ≥1% in immcells (35% v 16%, fisher test p = 0.27). PFS was not correlated with PDL1 expression.

Conclusions

Quantifying TILs is a simple prescreening strategy that may help select pts for CI therapy in ECT from otherwise unselected population. The value of adding PDL1 expression needs further investigation.

Clinical trial identification

Legal entity responsible for the study

VHIO.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

J. Tabernero: Advisory boards: Bayer, Boehringer Ingelheim, Genentech/Roche, Lilly, MSD, Merck Serono, Merrimack, Novartis, Peptomyc, Roche, Sanofi, Symphogen, Taiho. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.